Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist that activates two incretin hormone pathways. It is FDA-approved for type 2 diabetes management at doses from 2.5mg to 15mg weekly. The dual-agonist mechanism targets both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. Weight Method's compounded tirzepatide is a separate, individualized treatment overseen by your provider; individual results vary and no specific outcome can be promised.
Weight Method offers compounded semaglutide and tirzepatide programs from $199/month with virtual consultations and licensed providers who monitor your progress.
Key Fact
Tirzepatide activates GIP and GLP-1 receptors to reduce appetite. With Weight Method, your provider reviews your health profile, builds an individualized plan, and adjusts dosing based on how you respond over time. Outcomes differ widely from person to person.
Source: Provider-monitored, individualized treatment
Tirzepatide is a dual GIP/GLP-1 receptor agonist that reduces appetite. Weight Method's compounded tirzepatide is provider-monitored and individualized — results vary by person.
Tirzepatide is a dual GIP/GLP-1 receptor agonist; activating both pathways affects appetite and metabolism. Outcomes differ substantially from person to person depending on starting weight, adherence to lifestyle changes, and individual metabolic factors, and no specific amount of weight loss can be promised. Weight Method offers compounded tirzepatide with full clinical support and monitoring at $329/mo; your provider adjusts dosing throughout treatment.
Appetite suppression begins within 2-4 weeks at 2.5mg. Visible changes appear by weeks 10-14, with peak results occurring between months 3-9 at higher doses.
Initial appetite suppression and early changes in food preferences typically emerge within 2-4 weeks of starting Mounjaro at the 2.5mg dose. As the dose escalates through 5mg, 7.5mg, 10mg, and up to 15mg, weight loss accelerates — most patients see meaningful visible changes by weeks 10-14. The most substantial weight loss period occurs between months 3-9, driven by the compounding effect of dose titration and sustained behavioral changes. Maximum results in the SURPASS trials were observed around 40-52 weeks of treatment. Your Weight Method provider manages each dose transition to balance efficacy with tolerability.
Expect dose escalation from 2.5mg through 15mg over several months, individualized progress that varies by person, and potential benefit for GLP-1 partial responders.
Results with tirzepatide vary widely from person to person, and no specific amount of weight loss can be promised. The dual-mechanism approach means tirzepatide may work for some patients who have had suboptimal responses to GLP-1-only medications. Response tends to relate to the dose tolerated and individual factors. Weight Method's clinical team personalizes your treatment trajectory based on your goals and tolerability, and your provider is the right source for what you can realistically expect.
Patients with type 2 diabetes or insulin resistance see strong dual benefits. Those who plateaued on semaglutide alone may respond to tirzepatide's added GIP receptor activation.
Patients with type 2 diabetes or significant insulin resistance often see particularly strong dual benefits from Mounjaro's combined GIP/GLP-1 action. The dual-agonist mechanism may benefit individuals who plateaued on single GLP-1 receptor agonists like semaglutide. Higher baseline BMI patients tend to see larger absolute weight losses, though percentage reductions are consistent across weight categories. Strong early appetite suppression during the first month is a positive prognostic sign. Your Weight Method evaluation determines whether tirzepatide's dual mechanism is the optimal choice for your specific metabolic profile.
Take our 2-minute quiz to see if you qualify for GLP-1 treatment.
Start QuizFree consultation. No commitment.